BTS: Q3 weakness seems to improve already in Q4 - ABG - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Investeringsmöjlighet: Revolution på allergimarknaden – AcuCort banar väg för global framgång (annons)

Aktieanalys

BTS: Q3 weakness seems to improve already in Q4 - ABG

{newsItem.title}
ABG Sundal Collier Publicerad: 11 Nov 2022 09:10
BTS Group

Q3 adj. EBITA -20% vs ABGSCe due to North America
Guides for recovery in Q4 and reiterates 2022 guidance
Estimates down somewhat, share to follow


Q3 details

Sales SEK 617m (-2% vs ABGSCe 628m, no cons), adj. EBITA 66m (-20% vs ABGSCe 64m), adj. EBITA margin 10.7% (ABGSCe 13.2%). FX adjusted growth 12% (vs ABGSCe 15%). North America sales in Q3 grew 1% FX adjusted, Europe 26% and Other markets 23%.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/bts-group/Equity-research/2022/11/bts-group---q3-weakness-seems-to-improve-already-in-q4/

Nyheter om BTS Group

Läses av andra just nu

Om aktien BTS Group

Senaste nytt